Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

35.56 +0.49 (+1.40%)
Streaming Delayed Price Updated: 1:48 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 Next >
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
From Harmony Biosciences Holdings, Inc.
Via Business Wire
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
From Harmony Biosciences
Via Business Wire
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
From Harmony Biosciences
Via GlobeNewswire
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
From Kahn Swick & Foti, LLC
Via Business Wire
NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc. 
Via SBWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)
From Brodsky & Smith LLC
Via GlobeNewswire
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Techtronic, Boxed, Coinbase, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ:HRMY Shareholder Alert: Investigation over Possible Securities Laws Violations by Harmony Biosciences Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 04/14/2023 -- An investigation was announced for investors of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares over potential securities laws violations by Harmony... 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Nutanix and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.